A REVIEW ON AI DRIVEN DRUG DISCOVERY
Main Article Content
Keywords
Drug discovery, Insilico, Synthace, Disease, Researchers, BioNtech, Immune based treatment.
Abstract
Artificial intelligence is the present emerging technology even in the discovery of medicines. AI helps to speed up the work, reduce the cost of time, and gives more accurate decisions. In recent years few AI tools for drug development have been used. Insilico (chemistry 42) is designed to target a disease and design a new drug molecule, having already reached the advanced testing stages. SyntheX was pioneering intracellular drug discovery by using the synthetic biology and DNA-encoded libraries, which identify the small molecules and undruggable proteins. BioNtech and Instadeep have been created a lab which have been focused on the immune based treatment BioNtech brought Instadeep to involve deeper into its drug development process. NVIDIA clara Discovery offers high-powered tools to the researchers to stimulate the molecules and to analyze the data for brisk drug discovery and more scalable.
References
2. Platform Executive. AI in Drug Discovery: Speeding Up Development and Reducing Costs (2025–2030) [Internet]. 2025 Sep 17 [cited 2025 Nov 5]. Available from: https://www.platformexecutive.com/insight/health-care-research/ai-in-drug-discovery/
3. BestAI Blog. How AI is Slashing Drug Discovery and Development Costs: A New Era in Pharmaceutical Innovation [Internet]. 2025 May 19 [cited 2025 Nov 5]. Available from: https://blog.bestai.com/how-ai-is-slashing-drug-discovery-and-development-costs-a-new-era-in-pharmaceutical-innovation/
4. Ocana A, Pandiella A, Privat C, Bravo I, Luengo-Oroz M, Amir E, et al. Integrating artificial intelligence in drug discovery and early drug development: a transformative approach. Biomark Res [Internet]. 2025 Mar 14 [cited 2025 Nov 5];13(45). Available from: https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-025-00758-2
5. Insilico Medicine. Main Insilico Medicine [Internet]. 2025 [cited 2025 Nov 5]. Available from: https://insilico.com/
6. Zhavoronkov A, Ivanenkov YA, Aliper A, Veselov MS, Aladinskiy VA, Aladinskaya AV, et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nat Biotechnol [Internet]. 2019 Jan [cited 2025 Nov 5];37(1):103–6. Available from: https://www.nature.com/articles/s41587-018-0005-z
7. Insilico Medicine. Insilico Medicine Harnesses AI to Break the 12-Year Drug Development Curse [Internet]. GeneOnline; 2025 Jun 17 [cited 2025 Nov 5]. Available from: https://www.geneonline.com/insilico-medicine-harnesses-ai-to-break-the-12%E2%80%91year-drug-development-curse/
8. BioNTech SE. BioNTech Completes Acquisition of InstaDeep [Internet]. InstaDeep; 2023 Jul 31 [cited 2025 Nov 5]. Available from: https://instadeep.com/2023/07/biontech-completes-acquisition-of-instadeep/
9. InstaDeep. DeepChain Accelerate R&D and boost innovation and efficiency [Internet]. 2025 [cited 2025 Nov 5]. Available from: https://deepchain.bio/
10. InstaDeep. InstaDeep in Pharma [Internet]. 2025 [cited 2025 Nov 5]. Available from: https://instadeep.com/pharma/
11. BioNTech SE. BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update [Internet]. 2025 Nov 3 [cited 2025 Nov 5]. Available from: https://markets.businessinsider.com/news/stocks/biontech-announces-third-quarter-2025-financial-results-and-corporate-update-1035476282
12. Research and Markets. AI-Powered Clinical Trial Site Feasibility Research Report 2025: Market to Reach $3.55 Billion by 2029 [Internet]. GlobeNewswire; 2025 Nov 4 [cited 2025 Nov 5]. Available from: https://www.globenewswire.com/news-release/2025/11/04/3180613/28124/en/AI-Powered-Clinical-Trial-Site-Feasibility-Research-Report-2025-Market-to-Reach-3-55-Billion-by-2029-Fueled-by-Accelerated-Trial-Recruitment-Decentralized-Study-Models-and-Advanced.html
13. McKinsey & Company. Faster, smarter trials: Modernizing biopharma’s R&D IT applications [Internet]. 2025 Feb 13 [cited 2025 Nov 5]. Available from: https://www.mckinsey.com/industries/life-sciences/our-insights/faster-smarter-trials-modernizing-biopharmas-r-and-d-it-applications
14. SyntheX. About Us SyntheX Therapeutics [Internet]. 2025 [cited 2025 Nov 5]. Available from: https://www.synthexlabs.com/about/
15. Gainza P. AI Applications for Molecular Glue Degraders: From Degron Discovery to in silico Screening [Internet]. Targeted Protein Degradation Summit; 2022 Oct 26 [cited 2025 Nov 5]. Available from: https://ir.monterosatx.com/static-files/8806793a-99fb-4df8-8eb7-3785b39cf210
16. Plescia J. Degrader linker design for targeted protein degradation [Internet]. Cresset Group; 2024 May 14 [cited 2025 Nov 5]. Available from: https://cresset-group.com/science/science-resources/degrader-linker-design-targeted-protein-degradation/
17. NVIDIA. BioPharma Solutions for AI-Accelerated Drug Discovery [Internet]. 2025 [cited 2025 Nov 5]. Available from: https://www.nvidia.com/en-us/industries/healthcare-life-sciences/drug-discovery/
18. NVIDIA Corporation. Protein Structure Prediction With Predictive AI [Internet]. 2025 [cited 2025 Nov 5]. Available from: https://www.nvidia.com/en-gb/use-cases/protein-structure-prediction-with-predictive-ai/
19. NVIDIA Corporation. Protein Structure Prediction With Predictive AI [Internet]. 2025 [cited 2025 Nov 5]. Available from: https://www.nvidia.com/en-gb/use-cases/protein-structure-prediction-with-predictive-ai/
20. McKinsey & Company. The quantum revolution in pharma: Faster, smarter, and more precise [Internet]. 2025 Aug 25 [cited 2025 Nov 5]. Available from: https://www.mckinsey.com/industries/life-sciences/our-insights/the-quantum-revolution-in-pharma-faster-smarter-and-more-precise
21. Kipu Quantum GmbH. Kipu Quantum at AI in Drug Discovery 2025 [Internet]. 2025 Mar 24 [cited 2025 Nov 5]. Available from: https://kipu-quantum.com/knowledge-hub/blog/kipu-quantum-at-ai-in-drug-discovery-2025/
22. Shukla R, Bahl A. Transforming Clinical Trials with AI-Driven Protocol Optimization and Next-Gen Statistical Programming [Internet]. PHUSE US; 2025 [cited 2025 Nov 5]. Available from: https://www.lexjansen.com/phuse-us/2025/et/PAP_ET15.pdf
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Anuradha Nerella
Assistant Professor, Department of Pharmaceutics, VJ’s college of Pharmacy, Rajahmundry, Andhra Pradesh - India.
Dr. D Narendra
Principal & Professor, Department of Pharmaceutical analysis, VJ’s college of Pharmacy, Rajahmundry, Andhra Pradesh – India.
Devi Sai Santhoshi Sravya
Student, Department of Pharmacy, VJ’s college of Pharmacy, Rajahmundry, Andhra Pradesh – India.
Bindu Kalyani
Student, Department of Pharmacy, VJ’s college of Pharmacy, Rajahmundry, Andhra Pradesh – India.
Yagna Sri
Student, Department of Pharmacy, VJ’s college of Pharmacy, Rajahmundry, Andhra Pradesh – India.
Sravani Naga Sri
Student, Department of Pharmacy, VJ’s college of Pharmacy, Rajahmundry, Andhra Pradesh – India.
Neeraja
Student, Department of Pharmacy, VJ’s college of Pharmacy, Rajahmundry, Andhra Pradesh – India.